News
Marketed with promises such as ‘smell better everywhere’ or ‘keep fresh all over’, some claim to offer up to 72 hours of ...
22h
MyChesCo on MSNAclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis TreatmentWAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results